MedinCell SA · EURONEXT:MEDCL
MedinCell SA — FY2018/2019 Earnings Presentation
21 slides from MedinCell SA's earnings presentation, June 2019
Slide 1: Financial year results presentation, closing March 31 2019
Audioconference Financial year results presentation Closing March 31 2019
Slide 2: Agenda
Audioconference Agenda • Management presentation • Answers to shareholders' questions You can send your questions by using the chat on the right of your screen
Slide 3: Audio Conference speakers
Audio Conference • Christophe Douat • Jaime Arango CEO CFO • Nicolas Heuzé • Joël Richard Director Corporate Head of Technical & Development Pharmaceutical Operations & Corporate Finance
Slide 4: Christophe Douat
Christophe Douat •
Slide 5: Vision & Values
Vision & Values • Humanist Pharma • Employee shareholders • Power of the group, Adaptability, Innovation, Transparency, Directness, Trust, Have Fun •
Slide 6: Achievement of all anticipated milestones for 2018/2019
2018/2019 Achievement of all anticipated milestones for programs in development •
Slide 7: TEVA partnership
TEVA partnership • mdc-IRM Phase 3 in the US • mdc-TJK Preclinical •
Slide 8: Opioid free pain management
Opioid free pain management • mdc-CWM with AIC Phase 2 in the US • mdc-CMV Preclinical • mdc-NVA Formulation •
Slide 9: Contraception
Contraception • mdc-WWM 2nd tranche of the subvention from the Bill & Melinda Gates Foundation •
Slide 10: Products in formulation research
Products in formulation research •
Slide 11: Portfolio: 9 products
Portfolio • 9 products • 2 in clinical • 2 in preclinical • 5 in formulation research 5 with partners / 4 internal •
Slide 12: Christophe Douat
Christophe Douat •
Slide 13: Jaime Arango
Jaime Arango •
Slide 14: Financial highlights: cash & financial assets
Financial highlights • Cash & financial assets • 21,3 M€ cash & cash equivalent • 0,7 M€ risk-free & current financial assets • 3,9 M€ risk-free & non-current financial assets • 12,5 M€ potential (BEI) •
Slide 15: Financial highlights: financing operations
Financial highlights • Financing operations • 3,2 M€ Convertible bonds • 7,5 M€ EIB loan (of 20 M€) • 31,4 M€ IPO gross proceeds •
Slide 16: Revenue
Revenue • 4 M€ (vs 8,3 M€ in 2017/2018) •
Slide 17: Operating expenses
Operating expenses • 19,6 M€(+29% vs 2017/2018) • 11,9 M€ R&D (+35%) • 2,7 M€ Marketing et BD (+42%) • 4,9 M€ General Services (+15%) •
Slide 18: Financial expenses
Financial expenses • 4,2 M€ • 2,2 M€ (IPO) • 2 M€ (charges of existing debt) •
Slide 19: Debt
Debt • 27 M€ gross (vs 31 M€ 2017/2018) • 1,1 M€ net (vs 17,5 M€ 2017/2018) • 71% repayable after April 2023 •
Slide 20: Q&A
Q&A You can send your questions by using the chat on the right of your screen
Slide 21: Thank you
THANK YOU MedinCell 3, rue des frères Lumière www.medincell.com 34830 Jacou • France